Cargando…
Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab
The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpo...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697690/ https://www.ncbi.nlm.nih.gov/pubmed/31420544 http://dx.doi.org/10.1038/s41467-019-11556-4 |
_version_ | 1783444413647683584 |
---|---|
author | Serra-Peinado, Carla Grau-Expósito, Judith Luque-Ballesteros, Laura Astorga-Gamaza, Antonio Navarro, Jordi Gallego-Rodriguez, Jenny Martin, Mario Curran, Adrià Burgos, Joaquin Ribera, Esteban Raventós, Berta Willekens, Rein Torrella, Ariadna Planas, Bibiana Badía, Rosa Garcia, Felipe Castellví, Josep Genescà, Meritxell Falcó, Vicenç Buzon, Maria J. |
author_facet | Serra-Peinado, Carla Grau-Expósito, Judith Luque-Ballesteros, Laura Astorga-Gamaza, Antonio Navarro, Jordi Gallego-Rodriguez, Jenny Martin, Mario Curran, Adrià Burgos, Joaquin Ribera, Esteban Raventós, Berta Willekens, Rein Torrella, Ariadna Planas, Bibiana Badía, Rosa Garcia, Felipe Castellví, Josep Genescà, Meritxell Falcó, Vicenç Buzon, Maria J. |
author_sort | Serra-Peinado, Carla |
collection | PubMed |
description | The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpopulation of CD4-positive (CD4(+)) T lymphocytes from blood, with high levels of cell activation and heterogeneous memory phenotypes. In lymph node samples from infected patients, CD20 is present in productively HIV-infected cells, and ex vivo viral infection selectively upregulates the expression of CD20 during early infection. In samples from patients on antiretroviral therapy (ART) this subpopulation is significantly enriched in HIV transcripts, and the anti-CD20 monoclonal antibody Rituximab induces cell killing, which reduces the pool of HIV-expressing cells when combined with latency reversal agents. We provide a tool for targeting this active HIV-reservoir after viral reactivation in patients while on ART. |
format | Online Article Text |
id | pubmed-6697690 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-66976902019-08-19 Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab Serra-Peinado, Carla Grau-Expósito, Judith Luque-Ballesteros, Laura Astorga-Gamaza, Antonio Navarro, Jordi Gallego-Rodriguez, Jenny Martin, Mario Curran, Adrià Burgos, Joaquin Ribera, Esteban Raventós, Berta Willekens, Rein Torrella, Ariadna Planas, Bibiana Badía, Rosa Garcia, Felipe Castellví, Josep Genescà, Meritxell Falcó, Vicenç Buzon, Maria J. Nat Commun Article The identification of exclusive markers to target HIV-reservoir cells will represent a significant advance in the search for therapies to cure HIV. Here, we identify the B lymphocyte antigen CD20 as a marker for HIV-infected cells in vitro and in vivo. The CD20 molecule is dimly expressed in a subpopulation of CD4-positive (CD4(+)) T lymphocytes from blood, with high levels of cell activation and heterogeneous memory phenotypes. In lymph node samples from infected patients, CD20 is present in productively HIV-infected cells, and ex vivo viral infection selectively upregulates the expression of CD20 during early infection. In samples from patients on antiretroviral therapy (ART) this subpopulation is significantly enriched in HIV transcripts, and the anti-CD20 monoclonal antibody Rituximab induces cell killing, which reduces the pool of HIV-expressing cells when combined with latency reversal agents. We provide a tool for targeting this active HIV-reservoir after viral reactivation in patients while on ART. Nature Publishing Group UK 2019-08-16 /pmc/articles/PMC6697690/ /pubmed/31420544 http://dx.doi.org/10.1038/s41467-019-11556-4 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Serra-Peinado, Carla Grau-Expósito, Judith Luque-Ballesteros, Laura Astorga-Gamaza, Antonio Navarro, Jordi Gallego-Rodriguez, Jenny Martin, Mario Curran, Adrià Burgos, Joaquin Ribera, Esteban Raventós, Berta Willekens, Rein Torrella, Ariadna Planas, Bibiana Badía, Rosa Garcia, Felipe Castellví, Josep Genescà, Meritxell Falcó, Vicenç Buzon, Maria J. Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
title | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
title_full | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
title_fullStr | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
title_full_unstemmed | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
title_short | Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab |
title_sort | expression of cd20 after viral reactivation renders hiv-reservoir cells susceptible to rituximab |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697690/ https://www.ncbi.nlm.nih.gov/pubmed/31420544 http://dx.doi.org/10.1038/s41467-019-11556-4 |
work_keys_str_mv | AT serrapeinadocarla expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT grauexpositojudith expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT luqueballesteroslaura expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT astorgagamazaantonio expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT navarrojordi expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT gallegorodriguezjenny expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT martinmario expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT curranadria expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT burgosjoaquin expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT riberaesteban expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT raventosberta expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT willekensrein expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT torrellaariadna expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT planasbibiana expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT badiarosa expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT garciafelipe expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT castellvijosep expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT genescameritxell expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT falcovicenc expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab AT buzonmariaj expressionofcd20afterviralreactivationrendershivreservoircellssusceptibletorituximab |